NCT05630027

Brief Summary

Overall, 100 Caucasian subjects participated in this 6-weeks lasting study, AC5+ was applied daily. All subjects had clinically confirmed mild to moderate alopecia and self-declared sensitive scalp. Instrumental assessments included Trans Epidermal Water Loss (TEWL), inflammation markers, clinical assessments included the severity of erythema, inflammation and greasiness. Subjective/Self assessments comprised the intensity of the scalp itch/pruritus and the evaluation of their head hair status (volume, abundance, strength). Same assessments were provided by the investigators.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 2, 2019

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2020

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

November 18, 2022

Completed
11 days until next milestone

First Posted

Study publicly available on registry

November 29, 2022

Completed
Last Updated

November 29, 2022

Status Verified

November 1, 2022

Enrollment Period

1.5 years

First QC Date

November 18, 2022

Last Update Submit

November 18, 2022

Conditions

Keywords

alopeciasensitive skinprurit

Outcome Measures

Primary Outcomes (8)

  • erythema

    on a scale from o=none to 5=severe

    Baseline

  • erythema

    on a scale from o=none to 5=severe

    Day 21

  • inflammation

    on a scale from o=none to 5=severe

    Baseline

  • inflammation

    on a scale from o=none to 5=severe

    Day 21

  • greasiness

    on a scale from o=none to 5=severe

    Baseline

  • greasiness

    on a scale from o=none to 5=severe

    Day 21

  • Global soothing score

    sum of the symptoms with a score up to 15

    Baseline

  • Global soothing score

    sum of the symptoms with a score up to 15

    Day 21

Secondary Outcomes (18)

  • pruritus

    Baseline

  • pruritus

    Day 21

  • burning

    Baseline

  • burning

    Day 21

  • stinging

    Baseline

  • +13 more secondary outcomes

Interventions

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult subjects with mild alopecia and no dandruff

You may qualify if:

  • \>18 years
  • mild alopecia:
  • female: Ludwig type 1
  • male: Hamilton III to IV type

You may not qualify if:

  • Moderate or severe alopecia
  • Dandruff

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

L'OREAL Research and Innovation

Saint-Ouen, France

Location

MeSH Terms

Conditions

Alopecia

Interventions

piroctone olamine

Condition Hierarchy (Ancestors)

HypotrichosisHair DiseasesSkin DiseasesSkin and Connective Tissue DiseasesPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Philippe Massiot

    L'OREAL Research and Innovation, Saint-Ouen, France

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 18, 2022

First Posted

November 29, 2022

Study Start

January 2, 2019

Primary Completion

June 30, 2020

Study Completion

June 30, 2020

Last Updated

November 29, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share

Locations